港股创新药ETF（159567）涨0.20%，成交额14.40亿元

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1][2]. Group 1: Fund Performance - As of August 25, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 0.20% and a trading volume of 1.44 billion yuan [1]. - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - The latest share volume reached 6.167 billion shares, with a total fund size of 6.196 billion yuan, reflecting an increase of 1459.76% in share volume and 1540.06% in fund size since December 31, 2024 [1]. Group 2: Liquidity and Trading Activity - Over the past 20 trading days, the ETF has accumulated a trading volume of 41.093 billion yuan, averaging 2.055 billion yuan per day [1]. - Since the beginning of the year, the ETF has recorded a total trading volume of 170.432 billion yuan over 157 trading days, with an average daily trading volume of 1.086 billion yuan [1]. Group 3: Fund Holdings - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 100.96% during this period [2]. - Major holdings in the ETF include: - Innovent Biologics (9.52% holding, 263 million yuan market value) - WuXi Biologics (9.47% holding, 258 million yuan market value) - BeiGene (8.73% holding, 238 million yuan market value) - CanSino Biologics (7.62% holding, 208 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 196 million yuan market value) [2].